Review of rituximab in chop chemotherapy with chop only chemotherapy in treating aggressive Non Hodgkin's Lymphoma in elderly patients / Hazwan Ab Hamid
Background: The diffuse large B-cell lymphoma is a type of aggressive Non Hodgkin' s lymphoma (NHL) that is commonly found in elderly patients. CHOP chemotherapy has been used to treat this aggressive lymphoma. CHOP has brought several toxicities to patients especially to the elderly aggressiv...
Saved in:
| Main Author: | |
|---|---|
| Format: | Thesis |
| Language: | English |
| Published: |
2013
|
| Subjects: | |
| Online Access: | https://ir.uitm.edu.my/id/eprint/109522/1/109522.PDF https://ir.uitm.edu.my/id/eprint/109522/ |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Background: The diffuse large B-cell lymphoma is a type of aggressive Non Hodgkin' s lymphoma (NHL) that is commonly found in elderly patients. CHOP chemotherapy has been used to treat this aggressive lymphoma. CHOP has brought several toxicities to patients especially to the elderly aggressive NHL patients. New combination of chemo drug, rituximab was introduce lately and brings an impact to the old CHOP chemotherapy. Its efficacy is known better from CHOP only regimen. Method: Journals containing articles that are relevant to the subject of efficacy of rituximab in CHOP chemotherapy are gathered and systematic review and analysis was done to extract the information. Results: Several articles supported the hypothesis and confirmed its efficacy compared to CHOP only chemotherapy. And its toxicity towards the elderly patients is relevant. Conclusion: Rituximab plus CHOP is proven better than CHOP only chemotherapy in the term of its efficacy. |
|---|